| Detailed information |
|---|
| CancerLivER ID | 2027 |
| Biomarker | HMGB1 |
| Biomarker Name/Symbol (given in Publication) | HMGB1 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | A useful biomarker for radiologic responses to predict poor overall survival in patients with advanced HCC treated with sorafenib or HAIC. |
| Experimental Condition | HCC treated with sorafenib and with HAIC v/s Patients with Pre-treatment. |
| Cancer type | Human treated with sorafenib and HAIC |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 28474222 |
| Type of Biomarker | Predictive |
| Pathway | PI3 K/AKT/mTOR pathway |
| Cohort | 71 and 72 patients with advanced HCC treated with sorafenib and HAIC |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human treated with sorafenib and HAIC |
| Year of Publication | 2018 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT01882218 |